R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al.,

H. S. Phillips, S. Kharbanda, R. Chen, W. F. Forrest, R. H. Soriano et al., Molecular 552 subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, 553 and resemble stages in neurogenesis, N Engl J Med, vol.550, pp.157-73, 2005.

R. Verhaak, K. A. Hoadley, E. Purdom, V. Wang, Y. Qi et al., 555 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma 556 characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, vol.557, pp.98-110, 2010.

J. T. Huse, H. S. Phillips, and C. W. Brennan, Molecular subclassification of diffuse gliomas: 559 seeing order in the chaos, Glia, vol.59, pp.1190-1199, 2011.

S. Zheng, M. G. Chheda, and R. Verhaak, Studying a complex tumor: potential and 561 pitfalls, Cancer J Sudbury Mass, vol.18, pp.107-121, 2012.

A. Sottoriva, I. Spiteri, S. Piccirillo, A. Touloumis, V. P. Collins et al.,

, Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics, Natl Acad Sci U S A, vol.564, pp.4009-4023, 2013.

V. N. Patel, G. Gokulrangan, S. A. Chowdhury, Y. Chen, A. E. Sloan et al., 566 Network signatures of survival in glioblastoma multiforme, Nat Rev Clin Oncol, vol.567, pp.31-46, 2013.

R. S. Herbst, D. Morgensztern, and C. Boshoff, The biology and management of non-small 571 cell lung cancer, Nature, vol.553, pp.446-54, 2018.

C. H. June, R. S. O'connor, O. U. Kawalekar, S. Ghassemi, and M. C. Milone, CAR T cell 573 immunotherapy for human cancer, Science, vol.359, p.11, 2018.

S. C. Wei, C. R. Duffy, and J. P. Allison, Fundamental Mechanisms of Immune Checkpoint 575 Blockade Therapy, Cancer Discov, vol.8, pp.1069-86, 2018.

M. Lim, Y. Xia, C. Bettegowda, and M. Weller, Current state of immunotherapy for 577 glioblastoma, Nat Rev Clin Oncol, vol.15, p.14, 2015.

L. Boutin and E. Scotet, Towards Deciphering the Hidden Mechanisms That Contribute to 581 the Antigenic Activation Process of Human V?9V?2 T Cells, Front Immunol, vol.9, p.15, 2018.

C. Harly, Y. Guillaume, S. Nedellec, C. Peigné, H. Mönkkönen et al.,

A. Sandstrom, C. Peigné, A. Léger, J. E. Crooks, F. Konczak et al., The 586 intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation 587 of human V?9V?2 T cells, Immunity, vol.120, pp.490-500, 2012.

M. Bonneville, R. L. O'brien, and W. K. Born, Gammadelta T cell effector functions: a blend 589 of innate programming and acquired plasticity, Nat Rev Immunol, vol.10, p.18, 2010.

U. Jarry, C. Chauvin, N. Joalland, A. Léger, S. Minault et al., Stereotaxic 591 administrations of allogeneic human V?9V?2 T cells efficiently control the development of 592 human glioblastoma brain tumors, Oncoimmunology, vol.5, 2016.

. Tumors, M. Immunother-hagerstown-md-;-de-hoon, S. Imoto, J. Nolan, and S. Miyano, Open source clustering software, vol.41, pp.224-255, 1997.

B. R. Zeeberg, W. Feng, G. Wang, M. D. Wang, A. T. Fojo et al., GoMiner: a 599 resource for biological interpretation of genomic and proteomic data, Bioinforma Oxf Engl, vol.20, p.22, 2003.

M. Ashburner, C. A. Ball, J. A. Blake, D. Botstein, H. Butler et al., Gene 602 ontology: tool for the unification of biology. The Gene Ontology Consortium, Nat Genet, vol.603, pp.25-34, 2000.

K. Oizel, C. Chauvin, L. Oliver, C. Gratas, F. Geraldo et al., , p.605

, Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity. Clin 606, Cancer Res Off J Am Assoc Cancer Res, vol.23, p.24, 2017.

X. Leveque, M. Hochane, F. Geraldo, S. Dumont, C. Gratas et al., , p.608

, Pesticide Mixture Induces Accelerated Mesenchymal Stem Cell Aging In Vitro, Stem Cells 609 Dayt Ohio, vol.37, pp.1083-94, 2019.

U. Jarry, N. Joalland, C. Chauvin, B. Clemenceau, C. Pecqueur et al., Stereotactic 611 Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human 612

X. Glioblastoma-multiforme, J Vis Exp JoVE, 2018.

M. P. Lefranc, T. H. Rabbitts, A. Sandstrom, C. Peigné, A. Léger et al., The 616 intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation 617 of human V?9V?2 T cells, Res Immunol, vol.141, pp.490-500, 1990.

T. , Cell Immunotherapy in Cancer. Front Immunol, vol.9, p.29, 2018.

P. Wrobel, H. Shojaei, B. Schittek, F. Gieseler, B. Wollenberg et al., Lysis of 621 a broad range of epithelial tumour cells by human gamma delta T cells: involvement of 622 NKG2D ligands and T-cell receptor-versus NKG2D-dependent recognition, Histochem Cell 626 Biol, vol.66, p.31, 2007.

G. Chitadze, M. Lettau, S. Luecke, T. Wang, O. Janssen et al., NKG2D-and T-628 cell receptor-dependent lysis of malignant glioma cell lines by human ?? T cells: Modulation 629 by temozolomide and A disintegrin and metalloproteases 10, vol.17

L. S. Oncoimmunology-;-lamb, J. Bowersock, A. Dasgupta, G. Y. Gillespie, Y. Su et al., , vol.5, 2015.

, Engineered Drug Resistant ?? T Cells Kill Glioblastoma Cell Lines during a Chemotherapy 634 Challenge: A Strategy for Combining Chemo-and Immunotherapy, PLoS ONE, vol.635, p.2013, 2018.

M. Patel, M. A. Vogelbaum, G. H. Barnett, R. Jalali, and M. S. Ahluwalia, Molecular targeted 638 therapy in recurrent glioblastoma: current challenges and future directions, vol.21, pp.1247-66, 2012.

A. Sottoriva, I. Spiteri, S. Piccirillo, A. Touloumis, V. P. Collins et al.,

, Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics, Proc 642 Natl Acad Sci, vol.110, pp.4009-4023, 2013.

K. Oizel, C. Chauvin, L. Oliver, C. Gratas, F. Geraldo et al., , vol.644

, Mitochondrial Glutamine Targeting Prevails Over Glioblastoma Metabolic Plasticity, Clin, vol.645

, Cancer Res Off J Am Assoc Cancer Res, vol.23, p.36, 2017.

C. Ginestier, F. Monville, J. Wicinski, O. Cabaud, N. Cervera et al.,

H. Gober, M. Kistowska, L. Angman, P. Jenö, L. Mori et al., Human T cell 650 receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells, Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic 648 target, vol.30, p.39, 2003.

Q. Wang, B. Hu, X. Hu, H. Kim, M. Squatrito et al., Tumor evolution of 655 glioma intrinsic gene expression subtype associates with immunological changes in the 656 microenvironment, Cancer Cell, vol.32, p.658, 2017.

W. P. Vandertop, Treatment outcome of patients with recurrent glioblastoma multiforme: 659 a retrospective multicenter analysis, Cancer Immunol 662 Immunother CII, vol.135, pp.551-62, 2015.

J. Halliday, K. Helmy, S. S. Pattwell, K. L. Pitter, Q. Laplant et al., In vivo 664 radiation response of proneural glioma characterized by protective p53 transcriptional 665 program and proneural-mesenchymal shift, Proc Natl Acad Sci, vol.111, p.43, 2014.

T. Weiss, H. Schneider, M. Silginer, A. Steinle, M. Pruschy et al., , pp.2-667

L. S. Lamb, P. Musk, Z. Ye, F. Van-rhee, S. S. Geier et al., Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma. Clin 668, Cancer Res Off J Am Assoc Cancer Res, vol.24, pp.882-95, 2018.

, T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic 671 response, Bone Marrow Transplant, vol.27, pp.601-607, 2001.

, Right panel: Results are 740 expressed as specific median fluorescence intensity (MFI) (mean ± SD, p.741

. ***, Tumor cell surface phenotyping was 743 performed by flow cytometry using specific antibodies against ULBP 1, ULBP 2/5/6, ULBP 3 744 and MIC A/B expression. Histograms correspond to, respectively, CNP and MES GBM 745 cultures as in (B). Results are expressed as specific median fluorescence intensity (MFI) 746 (mean ± SD

, Allogeneic human V?9V?2 T lymphocytes efficiently eliminate primary 749 mesenchymal GBM cells in vivo

, Allogeneic 752 human V?9V?2 T lymphocytes were injected at the tumor site at days 7, 14 and 21 after 753 tumor cell implantation. Bottom panel Relative number of subjects at risk for each group and 754 median survival of GBM-1 tumor-bearing mice treated with V?9V?2 T lymphocytes are 755 indicated in the table, Mice treated with highly reactive V?9V?2 T lymphocytes were divided 756 in poor and good responders (R) (n=15 mice treated with poorly or highly reactive V?9V?2 T 757 lymphocytes, n=8 for poor responders and n=7 for good responders; Log-rank Test

, Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited